Is the use of COX-2 inhibitors in gastroenterology cost-effective?

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 1, Issue 2, 2004, Pages 60-61

  Graham, David Y ^a   Chan, Francis K L ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

COST-BENEFIT ANALYSIS; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; PEPTIC ULCER;

EID: 20444461160     PISSN: 17434378     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpgasthep0043     Document Type: Review

References (10)

1. Mann JR and DuBois RN (2004). Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 10: 145-152
2. Singh G and Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 56 (Suppl): S18-S24
3. Chan FK and Graham DY (2004) Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Aliment Pharmacol Ther 19: 1051-1061
4. Topol EJ and Falk GW (2004) A coxib a day won't keep the doctor away. Lancet 364: 639-640
5. Garcia Rodriguez LA and Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 769-772
6. El Serag HB et al. (2002) Prevention of complicated ulcer disease among chronic users of nonsteroidal antiinflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med 162: 2105-2110
7. Graham DY (2002) Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter 7: 1-8
8. Chan FK et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104-2110
9. Morris AL et al. (1994) Short report: the effect of misoprostol on the anaemia of NSAID enteropathy. Aliment Pharmacol Ther 8: 343-346
10. Laine L et al. (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124: 288-292